This systematic review examined cardiometabolic phenotypes and therapeutic response in adults with heart failure with preserved ejection fraction (HFpEF) or closely related heart failure populations from June 2025 to May 2026. The search included PubMed/MEDLINE, Scopus, and Web of Science, utilizing terms related to HFpEF, diabetes, obesity, adiposity, frailty, exercise function, and treatment outcomes. Six studies met the inclusion criteria, encompassing randomized trials, pooled analyses, and crossover trial evidence. These studies investigated tirzepatide, semaglutide, dapagliflozin, and dapagliflozin plus spironolactone, assessing their effects across various phenotypes.
Key Clinical Findings
Included studies evaluated outcomes related to type 2 diabetes, body mass index (BMI), central adiposity, achieved weight loss, epicardial or paracardiac fat, exercise limitation, frailty, and renal-electrolyte profile. Contemporary cardiometabolic therapies demonstrated improvements in heart failure outcomes, patient-reported health status, exercise capacity, body weight, natriuretic peptides, adiposity measures, cardiac remodeling markers, and frailty burden.
Diabetes did not uniformly attenuate heart failure benefit, despite less weight loss. Adiposity distribution, functional limitation, frailty, and local cardiac fat may represent clinically relevant domains for interpreting treatment response. Sodium-glucose cotransporter 2 inhibitor-based therapy showed potential cardiometabolic, renal, hemodynamic, and structural effects, requiring careful renal and potassium monitoring. Overall, the findings suggest a potential value of a phenotype-informed framework for evaluating treatment response in HFpEF. However, the evidence is primarily derived from secondary analyses, limiting its utility for phenotype-guided treatment selection. Prospective studies are needed to determine if integrating these factors can improve treatment selection beyond ejection fraction and BMI alone.